Emerging targets for the treatment of dyslipidemia

Current Medicinal Chemistry

Volumn 18, Issue 6, 2011, Pages 909-922

  Tavridou, A ^a   Ragia, G ^a   Manolopoulos, V G ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Antisense oligonucleotides; Cholesterol lowering agents; Dyslipidemia; HDL modifying agents; Microsomal triglyceride transfer protein inhibitors; Peroxisome proliferator activated receptor agonists; Squalene synthase inhibitors; Thyroid hormone receptor agonists

Indexed keywords

2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANACETRAPIB; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EPROTIROME; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; KEXIN; KEXIN TYPE 9; LAPAQUISTAT; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SOBETIROME; SODELGLITAZAR; SQUALENE SYNTHASE INHIBITOR; SUBTILISIN; THYROID HORMONE RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZARAGOZIC ACID A;

ACIDOSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; LIVER TOXICITY; MUSCLE DISEASE; MYOPATHY; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RISK REDUCTION; STRUCTURE ANALYSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BASE SEQUENCE; CHOLESTEROL; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; TRIGLYCERIDES;

EID: 79952789250     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794927757     Document Type: Article

References (155)

1. Austin, M.A.; Hokanson, J.E.; Edwards, K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol., 1998, 81, 7B-12B. (Pubitemid 28113939)
2. Baigent, C.; Keech, A.; Kearney, P.M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; Simes, R. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366, 1267-1278.
3. Downs, J.R.; Clearfield, M.; Weis, S.; Whitney, E.; Shapiro, D.R.; Beere, P.A.; Langendorfer, A.; Stein, E.A.; Kruyer, W.; Gotto, A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279, 1615-1622. (Pubitemid 28248586)
4. Gordon, D.J.; Probstfield, J.L.; Garrison, R.J.; Neaton, J.D.; Castelli, W.P.; Knoke, J.D.; Jacobs, D.R. Jr.; Bangdiwala, S.; Tyroler, H.A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989, 79, 8-15. (Pubitemid 19043669)
5. Grundy, S.M.; Cleeman, J.I.; Merz, C.N.; Brewer, H.B. Jr.; Clark, L.T.; Hunninghake, D.B.; Pasternak, R.C.; Smith, S.C. Jr.; Stone, N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol., 2004, 44, 720-732.
6. Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole, T.G.; Brown, L.; Warnica, J.W.; Arnold, J.M.; Wun, C.C.; Davis, B.R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 1996, 335, 1001-1009. (Pubitemid 26338729)
7. Smith, S.C. Jr.; Allen, J.; Blair, S.N.; Bonow, R.O.; Brass, L.M.; Fonarow, G.C.; Grundy, S.M.; Hiratzka, L.; Jones, D.; Krumholz, H.M.; Mosca, L.; Pasternak, R.C.; Pearson, T.; Pfeffer, M.A.; Taubert, K.A. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation, 2006, 113, 2363-2372.
8. Altschul, R.; Hoffer, A.; Stephen, J.D. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem., 1955, 54, 558-559.
9. Guyton, J.R.; Bays, H.E. Safety considerations with niacin therapy. Am. J. Cardiol., 2007, 99, 22C-31C.
10. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res., 1992, 33, 1569-1582.
11. Remick, J.; Weintraub, H.; Setton, R.; Offenbacher, J.; Fisher, E.; Schwartzbard, A. Fibrate therapy: An update. Cardiol. Rev., 2008, 16, 129-141. (Pubitemid 351549675)
12. van Heek, M.; Farley, C.; Compton, D.S.; Hoos, L.; Davis, H.R. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br. J. Pharmacol., 2001, 134, 409-417. (Pubitemid 32989139)
13. Mikhailidis, D.P.; Sibbring, G.C.; Ballantyne, C.M.; Davies, G.M.; Catapano, A.L. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. Opin., 2007, 23, 2009-2026. (Pubitemid 47300401)
14. Harris, W.S. n-3 fatty acids and serum lipoproteins: Human studies. Am. J. Clin. Nutr., 1997, 65, 1645S-1654S. (Pubitemid 27187958)
15. Harris, W.S.; Miller, M.; Tighe, A.P.; Davidson, M.H.; Schaefer, E.J. Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis, 2008, 197, 12-24.
16. Mozaffarian, D.; Rimm, E.B. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA, 2006, 296, 1885-1899. (Pubitemid 44596197)
17. Libby, P. The Forgotten Majority: Unfinished Business in Cardiovascular Risk Reduction. J. Am. Coll. Cardiol., 2005, 46, 1225-1228. (Pubitemid 41615541)
18. Kornbrust, D.J.; MacDonald, J.S.; Peter, C.P.; Duchai, D.M.; Stubbs, R.J.; Germershausen, J.I.; Alberts, A.W. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J. Pharmacol. Exp. Ther., 1989, 248, 498-505. (Pubitemid 19090215)
19. Masters, B.A.; Palmoski, M.J.; Flint, O.P.; Gregg, R.E.; Wang-Iverson, D.; Durham, S.K. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol. Appl. Pharmacol., 1995, 131, 163-174.
20. Ward, S.; Lloyd Jones, M.; Pandor, A.; Holmes, M.; Ara, R.; Ryan, A.; Yeo, W.; Payne, N. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol. Assess., 2007, 11, 1-160, iii-iv.
21. Tavridou, A.; Manolopoulos, V.G. Novel molecules targeting dyslipidemia and atherosclerosis. Curr. Med. Chem., 2008, 15, 792-802. (Pubitemid 351516796)
22. Amano, Y.; Nishimoto, T.; Tozawa, R.; Ishikawa, E.; Imura, Y.; Sugiyama, Y. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur. J. Pharmacol., 2003, 466, 155-161. (Pubitemid 36385101)
23. Nishimoto, T.; Ishikawa, E.; Anayama, H.; Hamajyo, H.; Nagai, H.; Hirakata, M.; Tozawa, R. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol. Appl. Pharmacol., 2007, 223, 39-45. (Pubitemid 47211267)
24. Bostedor, R.G.; Karkas, J.D.; Arison, B.H.; Bansal, V.S.; Vaidya, S.; Germershausen, J.I.; Kurtz, M.M.; Bergstrom, J.D. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J. Biol. Chem., 1997, 272, 9197-9203. (Pubitemid 27154927)
25. Charlton-Menys, V.; Durrington, P.N. Squalene synthase inhibitors : Clinical pharmacology and cholesterol-lowering potential. Drugs, 2007, 67, 11-16. (Pubitemid 46105084)
26. Biller, S.A.; Forster, C.; Gordon, E.M.; Harrity, T.; Rich, L.C.; Marretta, J.; Ciosek, C.P. Jr. Isoprenyl phosphinylformates: New inhibitors of squalene synthetase. J. Med. Chem., 1991, 34, 1912-1914.
27. Biller, S.A.; Forster, C.; Gordon, E.M.; Harrity, T.; Scott, W.A.; Ciosek, C.P. Jr. Isoprenoid (phosphinylmethyl)phosphonates as inhibitors of squalene synthetase. J. Med. Chem., 1988, 31, 1869-1871.
28. Baxter, A.; Fitzgerald, B.J.; Hutson, J.L.; McCarthy, A.D.; Motteram, J.M.; Ross, B.C.; Sapra, M.; Snowden, M.A.; Watson, N.S.; Williams, R.J.; et al. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J. Biol. Chem., 1992, 267, 11705-11708.
29. Bergstrom, J.D.; Kurtz, M.M.; Rew, D.J.; Amend, A.M.; Karkas, J.D.; Bostedor, R.G.; Bansal, V.S.; Dufresne, C.; VanMiddlesworth, F.L.; Hensens, O.D.; et al. Zaragozic acids: A family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA, 1993, 90, 80-84. (Pubitemid 23010253)
30. Vaidya, S.; Bostedor, R.; Kurtz, M.M.; Bergstrom, J.D.; Bansal, V.S. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch. Biochem. Biophys., 1998, 355, 84-92. (Pubitemid 28371155)
31. Amin, D.; Cornell, S.A.; Gustafson, S.K.; Needle, S.J.; Ullrich, J.W.; Bilder, G.E.; Perrone, M.H. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid Res., 1992, 33, 1657-1663.
32. Hiyoshi, H.; Yanagimachi, M.; Ito, M.; Ohtsuka, I.; Yoshida, I.; Saeki, T.; Tanaka, H. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: Comparison with 3-hydroxy-3- methylglutaryl-coa reductase inhibitors. J. Lipid Res., 2000, 41, 1136-1144. (Pubitemid 30483019)
33. Magnin, D.R.; Biller, S.A.; Chen, Y.; Dickson, J.K. Jr.; Fryszman, O.M.; Lawrence, R.M.; Logan, J.V.; Sieber-McMaster, E.S.; Sulsky, R.B.; Traeger, S.C.; Hsieh, D.C.; Lan, S.J.; Rinehart, J.K.; Harrity, T.W.; Jolibois, K.G.; Kunselman, L.K.; Rich, L.C.; Slusarchyk, D.A.; Ciosek, C.P. Jr. alpha- Phosphonosulfonic acids: Potent and selective inhibitors of squalene synthase. J. Med. Chem., 1996, 39, 657-660. (Pubitemid 26069686)
34. Dickson, J.K. Jr.; Biller, S.A.; Magnin, D.R.; Petrillo, E.W. Jr.; Hillyer, J.W.; Hsieh, D.C.; Lan, S.J.; Rinehart, J.K.; Gregg, R.E.; Harrity, T.W.; Jolibois, K.G.; Kalinowski, S.S.; Kunselman, L.K.; Mookhtiar, K.A.; Ciosek, C.P. Jr. Orally active squalene synthase inhibitors: Bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety. J. Med. Chem., 1996, 39, 661-664. (Pubitemid 26069687)
35. Sharma, A.; Slugg, P.H.; Hammett, J.L.; Jusko, W.J. Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharmacol. Res., 1998, 15, 1782-1786. (Pubitemid 28524592)
36. Brown, G.R.; Clarke, D.S.; Foubister, A.J.; Freeman, S.; Harrison, P.J.; Johnson, M.C.; Mallion, K.B.; McCormick, J.; McTaggart, F.; Reid, A.C.; Smith, G.J.; Taylor, M.J. Synthesis and activity of a novel series of 3- biarylquinuclidine squalene synthase inhibitors. J. Med. Chem., 1996, 39, 2971-2979. (Pubitemid 26251035)
37. McTaggart, F.; Brown, G.R.; Davidson, R.G.; Freeman, S.; Holdgate, G.A.; Mallion, K.B.; Mirrlees, D.J.; Smith, G.J.; Ward, W.H. Inhibition of squalene synthase of rat liver by novel 3' substituted quinuclidines. Biochem. Pharmacol., 1996, 51, 1477-1487.
38. Ugawa, T.; Kakuta, H.; Moritani, H.; Matsuda, K.; Ishihara, T.; Yamaguchi, M.; Naganuma, S.; Iizumi, Y.; Shikama, H. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol., 2000, 131, 63-70.
39. Ward, W.H.; Holdgate, G.A.; Freeman, S.; McTaggart, F.; Girdwood, P.A.; Davidson, R.G.; Mallion, K.B.; Brown, G.R.; Eakin, M.A. Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)-quinuclidine. Biochem. Pharmacol., 1996, 51, 1489-1501.
40. Miki, T.; Kori, M.; Mabuchi, H.; Tozawa, R.; Nishimoto, T.; Sugiyama, Y.; Teshima, K.; Yukimasa, H. Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J. Med. Chem., 2002, 45, 4571-4580.
41. Nishimoto, T.; Amano, Y.; Tozawa, R.; Ishikawa, E.; Imura, Y.; Yukimasa, H.; Sugiyama, Y. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br. J. Pharmacol., 2003, 139, 911-918. (Pubitemid 36877390)
42. Shiomi, M.; Yamada, S.; Amano, Y.; Nishimoto, T.; Ito, T. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Br. J. Pharmacol., 2008, 154, 949-957. (Pubitemid 351915051)
43. Burnett, J.R. Drug evaluation: TAK-475-an oral inhibitor of squalene synthase for hyperlipidemia. Curr. Opin. Investig. Drugs, 2006, 7, 850-856. (Pubitemid 44382792)
44. Davidson, M.H. Squalene synthase inhibition: A novel target for the management of dyslipidemia. Curr. Atheroscl. Rep., 2007, 9, 78-80. (Pubitemid 46075742)
45. Chrysselis, M.C.; Rekka, E.A.; Kourounakis, P.N. Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. J. Med. Chem., 2000, 43, 609-612. (Pubitemid 30127156)
46. Chrysselis, M.C.; Rekka, E.A.; Siskou, I.C.; Kourounakis, P.N. Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents. J. Med. Chem., 2002, 45, 5406-5409. (Pubitemid 35429179)
47. Tavridou, A.; Manolopoulos, V.G. EP2300 compounds: Focusing on the antiatherosclerotic properties of squalene synthase inhibitors. Curr. Pharm. Des., 2009, 15, 3167-3178.
48. Tavridou, A.; Kaklamanis, L.; Megaritis, G.; Kourounakis, A.P.; Papalois, A.; Roukounas, D.; Rekka, E.A.; Kourounakis, P.N.; Charalambous, A.; Manolopoulos, V.G. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur. J. Pharmacol., 2006, 535, 34-42.
49. Tavridou, A.; Manolopoulos, V.G. Antioxidant properties of two novel 2- biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. Eur. J. Pharmacol., 2004, 505, 213-221. (Pubitemid 39535694)
50. Tavridou, A.; Megaritis, G.; Kourounakis, A.P.; Charalambous, A.; Manolopoulos, V.G. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. Endothelium, 2007, 14, 239-243. (Pubitemid 47543010)
51. Tavridou, A.; Kaklamanis, L.; Papalois, A.; Kourounakis, A.P.; Rekka, E.A.; Kourounakis, P.N.; Charalambous, A.; Manolopoulos, V.G. EP2306 [2-(4- biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. J. Pharmacol. Exp. Ther., 2007, 323, 794-804. (Pubitemid 350146049)
52. Tavridou, A.; Kaklamanis, L.; Papalois, A.; Kourounakis, A.P.; Rekka, E.A.; Kourounakis, P.N.; Charalambous, A.; Manolopoulos, V.G. Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol- fed rabbit. J. Cardiovasc. Pharmacol., 2008, 51, 573-580.
53. Akdim, F.; Stroes, E.S.; Kastelein, J.J. Antisense apolipoprotein B therapy: Where do we stand? Curr. Opin. Lipidol., 2007, 18, 397-400. (Pubitemid 47051917)
54. Merki, E.; Graham, M.J.; Mullick, A.E.; Miller, E.R.; Crooke, R.M.; Pitas, R.E.; Witztum, J.L.; Tsimikas, S. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation, 2008, 118, 743-753.
55. Kastelein, J.J.; Wedel, M.K.; Baker, B.F.; Su, J.; Bradley, J.D.; Yu, R.Z.; Chuang, E.; Graham, M.J.; Crooke, R.M. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation, 2006, 114, 1729-1735. (Pubitemid 44607121)
56. Raal, F.J.; Santos, R.D.; Blom, D.J.; Marais, A.D.; Charng, M.J.; Cromwell, W.C.; Lachmann, R.H.; Gaudet, D.; Tan, J.L.; Chasan-Taber, S.; Tribble, D.L.; Flaim, J.D.; Crooke, S.T. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet, 2010, 375, 998-1006.
57. Frank-Kamenetsky, M.; Grefhorst, A.; Anderson, N.N.; Racie, T.S.; Bramlage, B.; Akinc, A.; Butler, D.; Charisse, K.; Dorkin, R.; Fan, Y.; Gamba- Vitalo, C.; Hadwiger, P.; Jayaraman, M.; John, M.; Jayaprakash, K.N.; Maier, M.; Nechev, L.; Rajeev, K.G.; Read, T.; Rohl, I.; Soutschek, J.; Tan, P.; Wong, J.; Wang, G.; Zimmermann, T.; de Fougerolles, A.; Vornlocher, H.P.; Langer, R.; Anderson, D.G.; Manoharan, M.; Koteliansky, V.; Horton, J.D.; Fitzgerald, K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA, 2008, 105, 11915-11920.
58. Zhang, D.W.; Lagace, T.A.; Garuti, R.; Zhao, Z.; McDonald, M.; Horton, J.D.; Cohen, J.C.; Hobbs, H.H. Binding of proprotein convertase subtilisin/ kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem., 2007, 282, 18602-18612. (Pubitemid 47100234)
59. Costet, P.; Krempf, M.; Cariou, B. PCSK9 and LDL cholesterol: Unravelling the target to design the bullet. Trends Biochem. Sci., 2008, 33, 426-434.
60. Lambert, G.; Charlton, F.; Rye, K.A.; Piper, D.E. Molecular basis of PCSK9 function. Atherosclerosis, 2009, 203, 1-7.
61. Abifadel, M.; Varret, M.; Rabes, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derre, A.; Villeger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003, 34, 154-156. (Pubitemid 36666925)
62. Cohen, J.C.; Boerwinkle, E.; Mosley, T.H. Jr.; Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med., 2006, 354, 1264-1272.
63. Duff, C.J.; Scott, M.J.; Kirby, I.T.; Hutchinson, S.E.; Martin, S.L.; Hooper, N.M. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem. J., 2009, 419, 577-584.
64. Chan, J.C.; Piper, D.E.; Cao, Q.; Liu, D.; King, C.; Wang, W.; Tang, J.; Liu, Q.; Higbee, J.; Xia, Z.; Di, Y.; Shetterly, S.; Arimura, Z.; Salomonis, H.; Romanow, W.G.; Thibault, S.T.; Zhang, R.; Cao, P.; Yang, X.P.; Yu, T.; Lu, M.; Retter, M.W.; Kwon, G.; Henne, K.; Pan, O.; Tsai, M.M.; Fuchslocher, B.; Yang, E.; Zhou, L.; Lee, K.J.; Daris, M.; Sheng, J.; Wang, Y.; Shen, W.D.; Yeh, W.C.; Emery, M.; Walker, N.P.; Shan, B.; Schwarz, M.; Jackson, S.M. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA, 2009, 106, 9820-9825.
65. Graham, M.J.; Lemonidis, K.M.; Whipple, C.P.; Subramaniam, A.; Monia, B.P.; Crooke, S.T.; Crooke, R.M. Antisense inhibition of proprotein conver tase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res., 2007, 48, 763-767. (Pubitemid 46557881)
66. Rashid, S.; Curtis, D.E.; Garuti, R.; Anderson, N.N.; Bashmakov, Y.; Ho, Y.K.; Hammer, R.E.; Moon, Y.A.; Horton, J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc. Natl. Acad. Sci. USA, 2005, 102, 5374-5379. (Pubitemid 40530265)
67. Lieu, H.D.; Withycombe, S.K.; Walker, Q.; Rong, J.X.; Walzem, R.L.; Wong, J.S.; Hamilton, R.L.; Fisher, E.A.; Young, S.G. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation, 2003, 107, 1315-1321. (Pubitemid 36314417)
68. Lan, H.; Pang, L.; Smith, M.M.; Levitan, D.; Ding, W.; Liu, L.; Shan, L.; Shah, V.V.; Laverty, M.; Arreaza, G.; Zhang, Q.; Murgolo, N.J.; Hernandez, M.; Greene, J.R.; Gustafson, E.L.; Bayne, M.L.; Davis, H.R.; Hedrick, J.A. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J. Cell Physiol., 2010, [Epub ahead of print].
69. Mayne, J.; Dewpura, T.; Raymond, A.; Cousins, M.; Chaplin, A.; Lahey, K.A.; Lahaye, S.A.; Mbikay, M.; Ooi, T.C.; Chretien, M. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis., 2008, 7, 22.
70. Hussain, M.M.; Shi, J.; Dreizen, P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res., 2003, 44, 22-32. (Pubitemid 36114766)
71. Wetterau, J.R.; Aggerbeck, L.P.; Bouma, M.E.; Eisenberg, C.; Munck, A.; Hermier, M.; Schmitz, J.; Gay, G.; Rader, D.J.; Gregg, R.E. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science, 1992, 258, 999-1001.
72. Chandler, C.E.; Wilder, D.E.; Pettini, J.L.; Savoy, Y.E.; Petras, S.F.; Chang, G.; Vincent, J.; Harwood, H.J. Jr. CP-346086: An MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J. Lipid Res., 2003, 44, 1887-1901. (Pubitemid 37356661)
73. Wetterau, J.R.; Gregg, R.E.; Harrity, T.W.; Arbeeny, C.; Cap, M.; Connolly, F.; Chu, C.H.; George, R.J.; Gordon, D.A.; Jamil, H.; Jolibois, K.G.; Kunselman, L.K.; Lan, S.J.; Maccagnan, T.J.; Ricci, B.; Yan, M.; Young, D.; Chen, Y.; Fryszman, O.M.; Logan, J.V.; Musial, C.L.; Poss, M.A.; Robl, J.A.; Simpkins, L.M.; Slusarchyk, W.A.; Sulsky, R.; Taunk, P.; Magnin, D.R.; Tino, J.A.; Lawrence, R.M.; Dickson, J.K. Jr.; Biller, S.A. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science, 1998, 282, 751-754. (Pubitemid 28489389)
74. Cuchel, M.; Bloedon, L.T.; Szapary, P.O.; Kolansky, D.M.; Wolfe, M.L.; Sarkis, A.; Millar, J.S.; Ikewaki, K.; Siegelman, E.S.; Gregg, R.E.; Rader, D.J. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med., 2007, 356, 148-156. (Pubitemid 46089675)
75. Cuchel, M.; Meagher, E.; Marais, A.D.; Blom, D.J.; Theron, H.D.; Baer, A.L.; Bloedon, L.T.; Sasiela, W.J.; Rader, D.J. A phase III study of microsomal triglyceride transfer protein inhibitor lomitapide (AEGR-733) in patients with homozygous familial hypercholesterolemia: Interim results at 6 months. Circulation, 2009, 120, S441-S441.
76. Samaha, F.F.; McKenney, J.; Bloedon, L.T.; Sasiela, W.J.; Rader, D.J. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5, 497-505.
77. Ellis, J.L.; Bartolozzi, A.; Ferkany, J.; Foudoulakis, H.; Kim, E.; Kuo, J.; Ruffing, R.; Schueller, O.; Wong, E.; Yang, Y.; Sweetnam, P. SLx-4090, an enterocyte-specific microsomal triglyceride transport protein inhibitor, lowers LDL cholesterol and triglycerides while raising HDL cholesterol in Apo E -/- mice fed a high-fat diet. Arterioscler. Thromb. Vasc. Biol., 2007, 27, E64-E64.
78. Prince, W.T.; Tong, W.; Andersen, G.; Campbell, S.; Ferkany, J.; Sweetnam, P.; Koester, F. SLx-4090: First human experience and proof of concept for an enterocyte-specific microsomal triglyceride transfer protein inhibitor. Circulation, 2006, 114, 2427-2427.
79. Robinson, E.; Grieve, D.J. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol. Ther., 2009, 122, 246-263.
80. Lalloyer, F.; Staels, B. Fibrates, glitazones, and peroxisome proliferatoractivated receptors. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 894-899.
81. Lindberg, M.; Astrup, A. The role of glitazones in management of type 2 diabetes. A dream or a nightmare? Obes. Rev., 2007, 8, 381-384. (Pubitemid 47283947)
82. Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356, 2457-2471. (Pubitemid 46919772)
83. Tesse, A.; Andriantsitohaina, R.; Ragot, T. PPARdelta activity in cardiovascular diseases: A potential pharmacological target. PPAR Res., 2009, 2009, 745821.
84. Sprecher, D.L. Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta. Am. J. Cardiol., 2007, 100, n20-24.
85. Jandeleit-Dahm, K.A.; Calkin, A.; Tikellis, C.; Thomas, M. Direct antiatherosclerotic effects of PPAR agonists. Curr. Opin. Lipidol., 2009, 20, 24-29.
86. Nissen, S.E.; Nicholls, S.J.; Wolski, K.; Howey, D.C.; McErlean, E.; Wang, M.D.; Gomez, E.V.; Russo, J.M. Effects of a potent and selective PPARalpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: Two randomized controlled trials. JAMA, 2007, 297, 1362-1373. (Pubitemid 46513237)
87. Millar, J.S.; Duffy, D.; Gadi, R.; Bloedon, L.T.; Dunbar, R.L.; Wolfe, M.L.; Movva, R.; Shah, A.; Fuki, I.V.; McCoy, M.; Harris, C.J.; Wang, M.D.; Howey, D.C.; Rader, D.J. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 140-146.
88. Karpf, D.; Roberts, B.; Martin, R.; Naim, S.; Shukla, U.; Choi, Y.; Krauss, R.; Francis, B.; Farrell, K.; Helmer, E.; Wang, X. MBX-8025, a potential novel treatment for dyslipidemia and metabolic syndrome: Results of a phase 2 proof-of-concept trial as monotherapy and in combination with atorvastatin. World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), 2008, Speakers abstracts http://www.codhy.com/2008/ Document.aspx?did=2113.
89. Sprecher, D.L.; Massien, C.; Pearce, G.; Billin, A.N.; Perlstein, I.; Willson, T.M.; Hassall, D.G.; Ancellin, N.; Patterson, S.D.; Lobe, D.C.; Johnson, T.G. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 359-365. (Pubitemid 46143052)
90. Riserus, U.; Sprecher, D.; Johnson, T.; Olson, E.; Hirschberg, S.; Liu, A.; Fang, Z.; Hegde, P.; Richards, D.; Sarov-Blat, L.; Strum, J.C.; Basu, S.; Cheeseman, J.; Fielding, B.A.; Humphreys, S.M.; Danoff, T.; Moore, N.R.; Murgatroyd, P.; O'Rahilly, S.; Sutton, P.; Willson, T.; Hassall, D.; Frayn, K.N.; Karpe, F. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes, 2008, 57, 332-339.
91. Ahmed, I.; Furlong, K.; Flood, J.; Treat, V.P.; Goldstein, B.J. Dual PPAR alpha/gamma agonists: Promises and pitfalls in type 2 diabetes. Am. J. Ther., 2007, 14, 49-62. (Pubitemid 46278670)
92. Nissen, S.E.; Wolski, K.; Topol, E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA, 2005, 294, 2581-2586. (Pubitemid 41697247)
93. Ratner, R.E.; Parikh, S.; Tou, C. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulintreated patients with type 2 diabetes. Diab. Vasc. Dis. Res., 2007, 4, 214-221. (Pubitemid 47529211)
94. Henry, R.R.; Lincoff, A.M.; Mudaliar, S.; Rabbia, M.; Chognot, C.; Herz, M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study. Lancet, 2009, 374, 126-135.
95. Tenenbaum, A.; Motro, M.; Fisman, E.Z. Dual and pan-peroxisome proliferator- activated receptors (PPAR) co-agonism: The bezafibrate lessons. Cardiovasc. Diabetol., 2005, 4, 14.
96. Ito, B.R.; Zhang, B.H.; Cable, E.E.; Song, X.; Fujitaki, J.M.; MacKenna, D.A.; Wilker, C.E.; Chi, B.; van Poelje, P.D.; Linemeyer, D.L.; Erion, M.D. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br. J. Pharmacol., 2009, 156, 454-465.
97. Trost, S.U.; Swanson, E.; Gloss, B.; Wang-Iverson, D.B.; Zhang, H.; Volodarsky, T.; Grover, G.J.; Baxter, J.D.; Chiellini, G.; Scanlan, T.S.; Dillmann, W.H. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology, 2000, 141, 3057-3064. (Pubitemid 32268991)
98. Grover, G.J.; Egan, D.M.; Sleph, P.G.; Beehler, B.C.; Chiellini, G.; Nguyen, N.H.; Baxter, J.D.; Scanlan, T.S. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: Selective actions relative to 3,5,3'-triiodo-L-thyronine. Endocrinology, 2004, 145, 1656-1661. (Pubitemid 38402372)
99. Scanlan, T.S. Sobetirome: A case history of bench-to-clinic drug discovery and development. Heart Fail. Rev., 2008, 15, 177-182.
100. Bryzgalova, G.; Effendic, S.; Khan, A.; Rehnmark, S.; Barbounis, P.; Boulet, J.; Dong, G.; Singh, R.; Shapses, S.; Malm, J.; Webb, P.; Baxter, J.D.; Grover, G.J. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J. Steroid Biochem. Mol. Biol., 2008, 111, 262-267.
101. Grover, G.J.; Mellstrom, K.; Malm, J. Development of the thyroid hormone receptor beta-subtype agonist KB-141: A strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc. Drug Rev., 2005, 23, 133-148. (Pubitemid 41278972)
102. Chirovsky, D.R.; Fedirko, V.; Cui, Y.; Sazonov, V.; Barter, P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: A systematic review. Eur. J. Cardiovasc. Prev. Rehabil., 2009, 16, 404-423.
103. Brown, B.G.; Stukovsky, K.H.; Zhao, X.Q. Simultaneous low-density lipoprotein- C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: A meta-analysis of 23 randomized lipid trials. Curr. Opin. Lipidol., 2006, 17, 631-636. (Pubitemid 44729955)
104. Brown, B.G.; Zhao, X.Q.; Chait, A.; Fisher, L.D.; Cheung, M.C.; Morse, J.S.; Dowdy, A.A.; Marino, E.K.; Bolson, E.L.; Alaupovic, P.; Frohlich, J.; Albers, J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med., 2001, 345, 1583-1592. (Pubitemid 33126837)
105. Liu, J.; Zhang, F.; Li, C.; Lin, M.; Briggs, M.R. Synergistic activation of human LDL receptor expression by SCAP ligand and cytokine oncostatin M. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 90-96. (Pubitemid 36091631)
106. Florentin, M.; Liberopoulos, E.N.; Wierzbicki, A.S.; Mikhailidis, D.P. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol., 2008, 23, 370-378. (Pubitemid 351787103)
107. Navab, M.; Hama, S.Y.; Anantharamaiah, G.M.; Hassan, K.; Hough, G.P.; Watson, A.D.; Reddy, S.T.; Sevanian, A.; Fonarow, G.C.; Fogelman, A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J. Lipid Res., 2000, 41, 1495-1508.
108. Navab, M.; Hama, S.Y.; Cooke, C.J.; Anantharamaiah, G.M.; Chaddha, M.; Jin, L.; Subbanagounder, G.; Faull, K.F.; Reddy, S.T.; Miller, N.E.; Fogelman, A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. J. Lipid Res., 2000, 41, 1481-1494.
109. Navab, M.; Berliner, J.A.; Subbanagounder, G.; Hama, S.; Lusis, A.J.; Castellani, L.W.; Reddy, S.; Shih, D.; Shi, W.; Watson, A.D.; Van Lenten, B.J.; Vora, D.; Fogelman, A.M. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 481-488. (Pubitemid 32323377)
110. Ansell, B.J.; Navab, M.; Hama, S.; Kamranpour, N.; Fonarow, G.; Hough, G.; Rahmani, S.; Mottahedeh, R.; Dave, R.; Reddy, S.T.; Fogelman, A.M. Inflammatory/ antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation, 2003, 108, 2751-2756. (Pubitemid 37498976)
111. Dimayuga, P.; Zhu, J.; Oguchi, S.; Chyu, K.Y.; Xu, X.O.; Yano, J.; Shah, P.K.; Nilsson, J.; Cercek, B. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem. Biophys. Res. Commun., 1999, 264, 465-468. (Pubitemid 29516109)
112. Mineo, C.; Deguchi, H.; Griffin, J.H.; Shaul, P.W. Endothelial and antithrombotic actions of HDL. Circ. Res., 2006, 98, 1352-1364. (Pubitemid 43948059)
113. Naqvi, T.Z.; Shah, P.K.; Ivey, P.A.; Molloy, M.D.; Thomas, A.M.; Panicker, S.; Ahmed, A.; Cercek, B.; Kaul, S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am. J. Cardiol., 1999, 84, 1011-1017. (Pubitemid 29505367)
114. Griffin, J.H.; Kojima, K.; Banka, C.L.; Curtiss, L.K.; Fernandez, J.A. Highdensity lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest., 1999, 103, 219-227. (Pubitemid 29053140)
115. Carson, S.D. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett., 1981, 132, 37-40. (Pubitemid 12248550)
116. Shepherd, J.; Packard, C.J.; Patsch, J.R.; Gotto, A.M. Jr.; Taunton, O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J. Clin. Invest., 1979, 63, 858-867. (Pubitemid 9182535)
117. Morrow, J.D.; Parsons, W.G., 3rd; Roberts, L.J. 2nd Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins, 1989, 38, 263-274. (Pubitemid 19206949)
118. Cheng, K.; Wu, T.J.; Wu, K.K.; Sturino, C.; Metters, K.; Gottesdiener, K.; Wright, S.D.; Wang, Z.; O'Neill, G.; Lai, E.; Waters, M.G. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. USA, 2006, 103, 6682-6687.
119. Lai, E.; De Lepeleire, I.; Crumley, T.M.; Liu, F.; Wenning, L.A.; Michiels, N.; Vets, E.; O'Neill, G.; Wagner, J.A.; Gottesdiener, K. Suppression of niacin- induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther., 2007, 81, 849-857. (Pubitemid 46788299)
120. Maccubbin, D.; Bays, H.E.; Olsson, A.G.; Elinoff, V.; Elis, A.; Mitchel, Y.; Sirah, W.; Betteridge, A.; Reyes, R.; Yu, Q.; Kuznetsova, O.; Sisk, C.M.; Pasternak, R.C.; Paolini, J.F. Lipid-modifying efficacy and tolerability of extended- release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int. J. Clin. Pract., 2008, 62, 1959-1970.
121. Barter, P.J.; Hopkins, G.J.; Calvert, G.D. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem. J., 1982, 208, 1-7. (Pubitemid 13215389)
122. Barter, P.J.; Brewer, H.B. Jr.; Chapman, M.J.; Hennekens, C.H.; Rader, D.J.; Tall, A.R. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 160-167. (Pubitemid 36231923)
123. Lewis, G.F.; Rader, D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res., 2005, 96, 1221-1232. (Pubitemid 40962099)
124. Qiu, X.; Mistry, A.; Ammirati, M.J.; Chrunyk, B.A.; Clark, R.W.; Cong, Y.; Culp, J.S.; Danley, D.E.; Freeman, T.B.; Geoghegan, K.F.; Griffor, M.C.; Hawrylik, S.J.; Hayward, C.M.; Hensley, P.; Hoth, L.R.; Karam, G.A.; Lira, M.E.; Lloyd, D.B.; McGrath, K.M.; Stutzman-Engwall, K.J.; Subashi, A.K.; Subashi, T.A.; Thompson, J.F.; Wang, I.K.; Zhao, H.; Seddon, A.P. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol., 2007, 14, 106-113.
125. Brousseau, M.E.; Schaefer, E.J.; Wolfe, M.L.; Bloedon, L.T.; Digenio, A.G.; Clark, R.W.; Mancuso, J.P.; Rader, D.J. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med., 2004, 350, 1505-1515. (Pubitemid 38477775)
126. McKenney, J.M.; Davidson, M.H.; Shear, C.L.; Revkin, J.H. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J. Am. Coll. Cardiol., 2006, 48, 1782-1790. (Pubitemid 44648632)
127. Bots, M.L.; Visseren, F.L.; Evans, G.W.; Riley, W.A.; Revkin, J.H.; Tegeler, C.H.; Shear, C.L.; Duggan, W.T.; Vicari, R.M.; Grobbee, D.E.; Kastelein, J.J. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial. Lancet, 2007, 370, 153-160. (Pubitemid 47042895)
128. Nicholls, S.J.; Nissen, S.E. New targets of high-density lipoprotein therapy. Curr. Opin. Lipidol., 2007, 18, 421-426. (Pubitemid 47051921)
129. Xie, L.; Li, J.; Xie, L.; Bourne, P.E. Drug discovery using chemical systems biology: Identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput. Biol., 2009, 5, e1000387.
130. Duriez, P.; Bordet, R.; Berthelot, P. The strange case of Dr HDL and Mr HDL: Does a NO's story illuminate the mystery of HDL's dark side uncovered by Dr HDL's drug targeting CETP? Med. Hypotheses, 2007, 69, 752-757. (Pubitemid 47260662)
131. Clark, R.W.; Ruggeri, R.B.; Cunningham, D.; Bamberger, M.J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res., 2006, 47, 537-552. (Pubitemid 43345595)
132. Schaefer, E.J.; Asztalos, B.F. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Curr. Opin. Cardiol., 2007, 22, 373-378. (Pubitemid 46897291)
133. de Grooth, G.J.; Kuivenhoven, J.A.; Stalenhoef, A.F.; de Graaf, J.; Zwinderman, A.H.; Posma, J.L.; van Tol, A.; Kastelein, J.J. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study. Circulation, 2002, 105, 2159-2165. (Pubitemid 34517159)
134. Kuivenhoven, J.A.; de Grooth, G.J.; Kawamura, H.; Klerkx, A.H.; Wilhelm, F.; Trip, M.D.; Kastelein, J.J. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol., 2005, 95, 1085-1088. (Pubitemid 40544314)
135. Stein, E.A.; Stroes, E.S.; Steiner, G.; Buckley, B.M.; Capponi, A.M.; Burgess, T.; Niesor, E.J.; Kallend, D.; Kastelein, J.J. Safety and tolerability of dalcetrapib. Am. J. Cardiol., 2009, 104, 82-91.
136. Krishna, R.; Garg, A.; Jin, B.; Keshavarz, S.S.; Bieberdorf, F.A.; Chodakewitz, J.; Wagner, J.A. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol., 2009, 67, 520-526.
137. Bloomfield, D.; Carlson, G.L.; Sapre, A.; Tribble, D.; McKenney, J.M.; Littlejohn, T.W., 3rd; Sisk, C.M.; Mitchel, Y.; Pasternak, R.C. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J., 2009, 157, 352-360 e352.
138. Cannon, C.P.; Dansky, H.M.; Davidson, M.; Gotto, A.M. Jr.; Brinton, E.A.; Gould, A.L.; Stepanavage, M.; Liu, S.X.; Shah, S.; Rubino, J.; Gibbons, P.; Hermanowski-Vosatka, A.; Binkowitz, B.; Mitchel, Y.; Barter, P. Design of the DEFINE trial: Determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am. Heart J., 2009, 158, 513-519 e513.
139. Ryan, U.S.; Rittershaus, C.W. Vaccines for the prevention of cardiovascular disease. Vasc. Pharmacol., 2006, 45, 253-257. (Pubitemid 44765287)
140. Davidson, M.H.; Maki, K.; Umporowicz, D.; Wheeler, A.; Rittershaus, C.; Ryan, U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis, 2003, 169, 113-120. (Pubitemid 36830929)
141. Rittershaus, C.W.; Miller, D.P.; Thomas, L.J.; Picard, M.D.; Honan, C.M.; Emmett, C.D.; Pettey, C.L.; Adari, H.; Hammond, R.A.; Beattie, D.T.; Callow, A.D.; Marsh, H.C.; Ryan, U.S. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2106-2112.
142. Thomas, L.J.; Hammond, R.A.; Forsberg, E.M.; Geoghegan-Barek, K.M.; Karalius, B.H.; Marsh, H.C. Jr.; Rittershaus, C.W. Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum. Vaccin., 2009, 5, 79-84.
143. Brewer, H.B. Jr.; Remaley, A.T.; Neufeld, E.B.; Basso, F.; Joyce, C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1755-1760. (Pubitemid 39350289)
144. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Van Lenten, B.J.; Datta, G.; Garber, D.; Fogelman, A.M. Potential clinical utility of high-density lipoprotein- mimetic peptides. Curr. Opin. Lipidol., 2006, 17, 440-444. (Pubitemid 44079483)
145. Nissen, S.E.; Tsunoda, T.; Tuzcu, E.M.; Schoenhagen, P.; Cooper, C.J.; Yasin, M.; Eaton, G.M.; Lauer, M.A.; Sheldon, W.S.; Grines, C.L.; Halpern, S.; Crowe, T.; Blankenship, J.C.; Kerensky, R. Effect of recombinant ApoAI Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA, 2003, 290, 2292-2300. (Pubitemid 37430562)
146. Hajj Hassan, H.; Blain, S.; Boucher, B.; Denis, M.; Krimbou, L.; Genest, J. Structural modification of plasma HDL by phospholipids promotes efficient ABCA1-mediated cholesterol release. J. Lipid Res., 2005, 46, 1457-1465. (Pubitemid 43109810)
147. Burgess, J.W.; Boucher, J.; Neville, T.A.; Rouillard, P.; Stamler, C.; Zachariah, S.; Sparks, D.L. Phosphatidylinositol promotes cholesterol transport and excretion. J. Lipid Res., 2003, 44, 1355-1363. (Pubitemid 37279617)
148. Burgess, J.W.; Neville, T.A.; Rouillard, P.; Harder, Z.; Beanlands, D.S.; Sparks, D.L. Phosphatidylinositol increases HDL-C levels in humans. J. Lipid Res., 2005, 46, 350-355. (Pubitemid 40271099)
149. Navab, M.; Anantharamaiah, G.M.; Reddy, S.T.; Hama, S.; Hough, G.; Grijalva, V.R.; Yu, N.; Ansell, B.J.; Datta, G.; Garber, D.W.; Fogelman, A.M. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 1325-1331.
150. Navab, M.; Anantharamaiah, G.M.; Hama, S.; Garber, D.W.; Chaddha, M.; Hough, G.; Lallone, R.; Fogelman, A.M. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation, 2002, 105, 290-292. (Pubitemid 34106174)
151. Barter, P.J.; Nicholls, S.; Rye, K.A.; Anantharamaiah, G.M.; Navab, M.; Fogelman, A.M. Antiinflammatory properties of HDL. Circ. Res., 2004, 95, 764-772. (Pubitemid 39390578)
152. Bloedon, L.T.; Dunbar, R.; Duffy, D.; Pinell-Salles, P.; Norris, R.; DeGroot, B.J.; Movva, R.; Navab, M.; Fogelman, A.M.; Rader, D.J. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res., 2008, 49, 1344-1352.
153. Bailey, D.; Jahagirdar, R.; Gordon, A.; Hafiane, A.; Campbell, S.; Chatur, S.; Wagner, G.S.; Hansen, H.C.; Chiacchia, F.S.; Johansson, J.; Krimbou, L.; Wong, N.C.; Genest, J. RVX-208: A small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol., 2010, 55, 2580-2589.
154. Waksman, R.; Torguson, R.; Kent, K.M.; Pichard, A.D.; Suddath, W.O.; Satler, L.F.; Martin, B.D.; Perlman, T.J.; Maltais, J.A.; Weissman, N.J.; Fitzgerald, P.J.; Brewer, H.B. Jr. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated highdensity lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol., 2010, 55, 2727-2735.
155. Campbell, C.Y.; Rivera, J.J.; Blumenthal, R.S. Residual risk in statin-treated patients: Future therapeutic options. Curr. Cardiol. Rep., 2007, 9, 499-505. (Pubitemid 350081422)